The new Presidential Administration has hardly settled in before being confronted with a stark choice: will they continue policies that foster public/private sector R&D partnerships or be diverted down a path that’s been a dead-end? President Biden faces two herculean tasks: getting the COVID-19 pandemic under control while reviving the economy. The problems are intertwined and require continuous innovation to overcome, which means tapping the best minds in our public and private sectors. We’ve just witnessed a modern miracle, as such partnerships seamlessly came together to create effective COVID-19 vaccines and therapies in record time. But the policies these collaborations depend on are now being questioned.
Recent Posts
- Squires Emphasizes AI, Dubs Inherited Backlog ‘An Absolute Dumpster Fire’ and a ‘Betrayal’
 - Federal Circuit Clarifies Precedent on Pre-AIA Prior Art ‘By Another’
 - Squires Restores PTAB’s RPI Identification Requirement to Exacting Pre-SharkNinja Standard
 - Tariffs, Tech Wars, and Patent Turmoil: Navigating IP Strategy in a Rapidly Changing World | IPWatchdog Unleashed
 - Life Sciences Masters Panelists Lament Mounting Policy Uncertainty
 
